Strategic Disinvestment of IMPCL to Skymap Pharma – Rs 121.01 Cr Deal Approved

The Ministry of Finance has approved the sale of 100% equity of Indian Medicines Pharmaceutical Corporation Limited (IMPCL) to Skymap Pharmaceuticals Private Ltd. for Rs 121,00,94,400 (≈ ₹121.01 crore). The transaction follows a Strategic Disinvestment policy approved by the Cabinet Committee on Economic Affairs (CCEA) . Key Developments Two‑stage competitive bidding was conducted from September 2023 to January 2026. Seven interested parties submitted Expressions of Interest; all qualified as bidders. After technical and financial evaluation, Skymap Pharmaceuticals Pvt. Ltd. emerged as the highest bidder, offering a price above the reserve price. The Alternative Mechanism gave final approval on the bid amount. The Letter of Award has been issued, and the Secretaries of DIPAM and AYUSH are authorized to close the transaction. Important Facts IMPCL was incorporated on 12 July 1978 with the mandate to produce standardised Ayurvedic and Unani medicines. The CCEA gave an “in‑principle” approval for its strategic disinvestment in November 2017 . The Preliminary Information Memorandum (PIM) was released on 01 September 2023 , and the Request for Proposal (RFP) with the Share Purchase Agreement (SPA) was issued on 01 December 2025 . Two sealed financial bids were received by the deadline of 20 January 2026 . UPSC Relevance This case illustrates the government's approach to monetising public assets, a key topic under GS 3 – Economy . It highlights the procedural framework for disinvestment, involving multiple layers of approval – from the Inter‑Ministerial Group to the Core Group of Secretaries on Disinvestment . Understanding the role of ministries like AYUSH and the strategic importance of the pharmaceutical sector is essential for questions on health policy and public‑private partnership. Way Forward Following the award, the successful bidder will take over management control of IMPCL. The transaction is expected to bring fresh capital, modernise production facilities, and improve market reach for Ayurvedic and Unani medicines. The government will monitor the post‑disinvestment performance through DIPAM , ensuring that the strategic objectives of revenue generation and sectoral growth are met.